Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium.
Han JX, Koh MJ, Boussi L, Sorial M, McCabe SM, Peng L, Singh S, Eche-Ugwu IJ, Gabler J, Fernandez Turizo MJ, MacVicar CT, Garg AR, Disciullo A, Chopra K, Lenart AW, Nwodo E, Barnes JA, Koh MJ, Miranda ECM, Chiattone CS, Stuver RN, Horwitz SM, Merrill MH, Jacobsen ED, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim YR, Kim JS, Cho JY, Eipe T, Shet T Dr, Epari S, Shetty A, Saha S, Jain H Dr, Sengar M MD, DM, Van Der Weyden C, Prince HM, Hamouche R, Muradashvili T, Foss FM, Gentilini M, Casadei B, Zinzani PL, Okatani T, Yoshida N, Yoon SE, Kim WS, Panchoo G, Mohamed Z, Verburgh E, Alturas JC, Al-Mansour M, Ford J, Cabrera ME, Ku A, Bhagat G, Ma H, Sawas A, Kariya KM, Iwasaki M, Bhanushali F, O'Connor OA, Marchi E, Shen C, Shah D, Jain S. Han JX, et al. Among authors: stuver rn. Blood Adv. 2024 Oct 31:bloodadvances.2024014674. doi: 10.1182/bloodadvances.2024014674. Online ahead of print. Blood Adv. 2024. PMID: 39481087
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.
Johnson WT, Epstein-Peterson ZD, Ganesan N, Pak T, Chang T, Dao P, Moskowitz AJ, Stuver RN, Ghione P, Galasso N, Khan N, Palomba ML, Caron PC, Kumar A, Tamari R, Lue JK, Noy A, Falchi L, Intlekofer AM, Gyurkocza B, Perales MA, Scordo M, Herskovits AZ, Salles G, Vardhana SA, Horwitz SM. Johnson WT, et al. Among authors: stuver rn. Haematologica. 2024 Sep 1;109(9):2998-3003. doi: 10.3324/haematol.2023.284179. Haematologica. 2024. PMID: 38752279 Free PMC article. No abstract available.
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy.
Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, Galasso N, Chang T, Khan N, Aypar U, Lewis NE, Zelenetz AD, Palomba ML, Matasar MJ, Noy A, Hamilton AM, Hamlin P, Caron PC, Straus DJ, Intlekofer AM, Lee Batlevi C, Kumar A, Owens CN, Sauter CS, Falchi L, Lue JK, Vardhana SA, Salles G, Dogan A, Schultz ND, Arcila ME, Horwitz SM. Johnson WT, et al. Among authors: stuver rn. Blood Adv. 2023 Sep 12;7(17):5172-5186. doi: 10.1182/bloodadvances.2023009953. Blood Adv. 2023. PMID: 37078708 Free PMC article.
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.
Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Stuver RN, et al. Am J Hematol. 2019 Jun;94(6):641-649. doi: 10.1002/ajh.25463. Epub 2019 Apr 9. Am J Hematol. 2019. PMID: 30896890 Free PMC article. Clinical Trial.